Skip to main content
Signal8
Im Ellie Eunkyung profile photo

Ellie Eunkyung Im

CIK: 0002075219

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

CRESCENT BIOPHARMA, INC. logo
CBIO

CRESCENT BIOPHARMA, INC.

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

  • CRESCENT BIOPHARMA, INC. logo
    CBIO

    CRESCENT BIOPHARMA, INC.

    Sep 16, 2026
    Sale(S)
    Direct
    623 shares at avg. $17.90$11K
  • CRESCENT BIOPHARMA, INC. logo
    CBIO

    CRESCENT BIOPHARMA, INC.

    Jun 22, 2026
    Sale(S)
    Direct
    1.2K shares at avg. $17.99$22K
  • CRESCENT BIOPHARMA, INC. logo
    CBIO

    CRESCENT BIOPHARMA, INC.

    Dec 15, 2025
    Award(A)
    Direct
    16.3K shares-
  • CRESCENT BIOPHARMA, INC. logo
    CBIO

    CRESCENT BIOPHARMA, INC.

    Dec 15, 2025
    Award(A)
    Direct
    5K shares-

1-4 of 4

About Im Ellie Eunkyung

Im Ellie Eunkyung (SEC CIK 0002075219) files insider reports with the SEC as Chief Medical Officer of CRESCENT BIOPHARMA, INC. (CBIO).

Signal8 holds 4 ownership filings by Im Ellie Eunkyung (1 Form 3, 3 Form 4), filed between Jun 30, 2025 and Sep 18, 2026. Those filings report 4 transactions, from Dec 15, 2025 to Sep 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Im Ellie Eunkyung's filings is in WALTHAM, MA.

Recent filings by Im Ellie Eunkyung

  • Sep 16, 2026: Open-market sale of CBIO shares (Form 4, code S).
  • Jun 22, 2026: Open-market sale of CBIO shares (Form 4, code S).
  • Dec 15, 2025: Grants or awards of CBIO shares (2 lines, Form 4, code A).

Other insiders filing for CRESCENT BIOPHARMA, INC. (CBIO)

How to read Form 4 transaction codes